|
|
Glaucoma Treatments in 2021: Personalizing Patient Needs
This continuing medical education (CE/CME) activity captures content from a roundtable in August.
Activity Description
Based on a roundtable held in August, this supplement summarizes a discussion of the mechanisms of actions and challenges with currently available and novel therapeutics as well as how to personalize glaucoma treatments.
Target Audience
This certified CME/CE activity is designed eye care providers involved in the management of glaucoma and associated disorders. |
|
|
Recognition and Referral: Best Practices for Managing Patients with GA
Patients with advanced dry age-related macular degeneration can present with geographic atrophy (GA), a disease that is progressive and increases with age. Although there is no treatment approved by the FDA that halts or reverses GA, a number of drugs in the pipeline are designed to address GA progression, hoping to succeed where previous drug candidates failed. This series of regional, interactive, virtual symposia are designed to educate eye care providers on the importance of diagnosis and ... |
|
|
Putting Patients First: Best Practices for Neurotrophic Keratitis Diagnosis and Treatment
This previously recorded satellite symposium features an engaging presentation on the potential causes of neurotrophic keratitis, how to differentiate it from similar diseases, and when referrals may be necessary. Treatment options will also be discussed, including the mechanisms of action of newer therapies and when they should be introduced.
Case discussions and audience question-and-answer session were also recorded. |
|
|
Individualizing Glaucoma Treatment: Understanding How to Utilize Traditional and Novel Agents
Join Nathan M. Radcliffe, MD, and Justin Schweitzer, OD, FAAO, as they discuss the ways in which novel therapeutics may help to overcome the challenges and limitations associated with currently available pharmacologic treatment options for ocular hypertension and primary open-angle glaucoma. |
|
|
Neurotrophic Keratitis: Old Problem, New Solutions
Eye care providers may not understand what neurotrophic keratitis is or how it differs from other corneal diseases. In addition; eye care practitioners may be unaware of treatments in development, or the already approved treatments for neurotrophic keratitis. They also may not understand the mechanism of action of these newer treatments. |
|